Daniel Ciccarone, MD, MPH.
Justine Miner Professor of Addiction Medicine at the University of California San Francisco.
Dr. Ciccarone is a member of the scientific advisory board for Celero Systems. Relevant financial relationships listed for the author have been mitigated.
Alyssa Falleni, PharmD. CT Health Education and Research in SUD and Related Harms (CHERISH) Fellow; VA Connecticut Healthcare System, Orange, CT.
Noah Capurso, MD, MHS. Assistant Professor of Psychiatry, Yale University, New Haven, CT; Editor-in-Chief of The Carlat Addiction Treatment Report.
Dr. Falleni and Dr. Capurso have no financial relationships with companies related to this material.
John Wang, MD, and Deepti Anbarasan, MD. Dr. Wang and Dr. Anbarasan have no financial relationships with companies related to this material.
Peter J. Farago, MD. Dr. Farago has no financial relationships with companies related to this material.
Shram Shukla, MD. Addiction psychiatry fellow, Yale School of Medicine. New Haven, CT.
Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University. New Haven, CT. Editor-in-chief of The Carlat Addiction Treatment Report.
Dr. Shukla and Dr. Capurso have no financial relationships with companies related to this material.
Bryan K. Tolliver, MD, PhD
Associate professor, Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina. Charleston, SC.
Dr. Tolliver has no financial relationships with companies related to this material.
“When tailoring medication choice, a careful history can guide you. If I’m treating a patient who drinks excessively at night to sleep or who struggles with insomnia when they try to stop drinking, I’ll start with a sedating antidepressant like mirtazapine. That’s not an evidence-based decision, it’s a clinical decision that I think can be helpful.”
David Beckmann, MD, MPH.
Assistant professor of psychiatry and human behavior, Sidney Kimmel Medical College, Thomas Jefferson University. Philadelphia, PA.
Dr. Beckmann has no financial relationships with companies related to this material.
Julio Cesar Nunes, MD. Psychiatry resident, Yale University. New Haven, CT.
Noah Capurso, MD, MHS. Assistant professor of psychiatry, Yale University. New Haven, CT. Editor-in-chief of The Carlat Addiction Treatment Report.
Dr. Nunes and Dr. Capurso have no financial relationships with companies related to this material.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
RSS
